CUREator+ Dementia and Cognitive Decline program

CUREator+ Dementia and Cognitive Decline program is sponsored by Brandon BioCatalyst (funded by the Federal Government's Medical Research Future Fund (MRFF)). This opportunity supports mission-aligned projects and measurable outcomes.

CUREator Programs – Brandon BioCatalyst Biotech Innovators Program Cicada x Brandon BioCatalyst at Westmead Brandon BioCatalyst Internship Women in Leadership Development (WILD) Process and Investment Review Committee OPEN ROUND: BioMedTech Incubator CUREator manages multiple grant funding programs that support the development and commercialisation of health innovations across a range of areas and technology types.

The programs are summarised below. CUREator BioMedTech Incubator (BMTI) BioMedTech Incubator (BMTI) Supporting therapeutics innovations at the preclinical and clinical stages. Up to $5m per project.

New startups, jobs, patents, investment, patient impact. CUREator in partnership with Australia’s national science agency, CSIRO , is delivering a national program funded by the Australian Government’s Medical Research Future Fund (MRFF) through the BioMedTech Incubator (BMTI) initiative.

The program is designed to accelerate the development and maturation of early-stage therapeutic innovations addressing significant unmet medical needs. The program will provide significant non-dilutive funding to early stage biotech startups, along with access to hands-on support, training programs, mentorship, commercial guidance, international expert networks, and investment capital.

Using a unique model to prepare teams for the discipline expected by private capital and to ensure investment is directed to the most promising projects, funding will be released in tranches tied to mutually agreed milestones, with high-performing programs able to apply for competitive top-up funding. Details about the program can be found on the CUREator BMTI program page .

CUREator+ Dementia & Cognitive Decline Dementia & Cognitive Decline BMTI CUREator+. Early & later stage dementia & cognitive decline related health innovations. Investment, dementia patient and careers impact CUREator+ Dementia & Cognitive Decline is a national incubator program funded by the Australian Government’s Medical Research Future Fund (MRFF) through the BioMedTech Incubator (BMTI) initiative.

The program is delivered in partnership between Brandon BioCatalyst’s CUREator, ANDHealth , and Dementia Australia , and aims to accelerate the commercialisation of early-stage Australian innovations addressing dementia and cognitive decline. CUREator+ Dementia & Cognitive Decline provides non-dilutive funding, along with access to investment capital, commercial guidance, international expert networks, and mentorship.

Eligible technologies include therapeutics (novel and repurposed), biomarkers, diagnostics, medical and assistive devices, and digital health technologies. Projects may be at the preclinical, clinical or commercial development stage, and must demonstrate a clear path to impact and commercialisation. Maturing Biomedtech and Digital health innovations.

Investment, patient impact CUREator+ is a national incubator program funded by the Australian Government’s Medical Research Future Fund (MRFF) through the BioMedTech Incubator (BMTI) initiative.

The program is delivered in partnership between Brandon BioCatalyst’s CUREator and ANDHealth , and aimed to accelerate the commercialisation of early-stage Australian medical research and innovation across a broad range of therapeutic areas and technology types.

CUREator+ provided non-dilutive funding to small-to-medium enterprises (SMEs), along with access to investment capital, commercial guidance, international expert networks, and mentorship. Eligible technologies included novel and repurposed therapeutics, diagnostics, medical devices, and digital health technologies.

Projects are supported at the preclinical, clinical, or commercial development stage and are selected based on their potential for impact and commercialisation. Stage 1 : Funding between $1 million to $2. 5 million, provided in tranches aligned with milestones.

Projects have up to 2 years to complete activities. Stage 2 : Competitive top-up funding for Stage 1 projects, up to a total of $5 million per project. Projects have up to 4 years to complete both stages.

Stage 1 was delivered through two open, competitive rounds. CUREator+ awardees can be found here for Round 1. Supporting preclinical medical research and innovation.

New startups, jobs, patents, investment. Funded by the Australian Government’s Medical Research Future Fund (MRFF) Early Stage Translation and Commercialisation Support (ESTAC) initiative, this program targets preclinical-stage biomedical technologies and supports their transition toward investment and partnership readiness.

The Preclinical Stream provides non-dilutive grant funding of up to $500,000 per project, supporting Australian preclinical medical research and innovation with commercial potential. Projects focus on key experiments and milestones to de-risk assets, confirm proof of concept, and improve commercial positioning. Awardees of the Preclinical Stream can be found here for Round 1, and here for Round 2.

Awardees could apply for additional ‘top-up’ funding upon meeting key project-specific milestones, further supporting their journey towards successful commercialisation. Top-up funding for the Preclinical Stream was offered through three competitive rounds. ‘Top-up’ awardees of the Preclinical Stream can be found here .

Supporting clinical development of therapeutics. Investment, patient impact. Funded by the Australian Government’s Medical Research Future Fund (MRFF) Early Stage Translation and Commercialisation Support (ESTAC) initiative, this program targets clinical-stage therapeutics, enabling them to conduct clinical development programs to become investment—or partnership-ready.

The Clinical Stream provides non-dilutive grant funding of up to $1,500,000 per project, supporting Australian clinical-stage medical research and innovation with commercial potential. Awardees of the Clinical Stream can be found here for Round 1, here for Round 2 and here for Round 3. CUREator: CSIRO Health Security Supporting health security innovations.

Investment, national capability, health security outcomes. Funded by CSIRO, Australia’s National Science Agency, this program supports the development of health security and medical countermeasure technologies, aiming to enhance Australia’s preparedness and responsiveness to emerging human health threats.

The Health Security Stream provides non-dilutive grant funding of up to $500,000 per project for technologies addressing Australia’s human health security or addressing known capability or capacity gaps for national health security including but not limited to: Infectious disease resilience Preparedness and response Manufacturing related to health security Awardees of the Health Security Stream can be found here .

Awardees meeting key project-specific milestones were eligible to apply for competitive top-up funding, which further supported their journey towards successful commercialisation. ‘Top-up’ awardees of the Health Security Stream can be found here . CUREator: Minimising Antimicrobial Resistance Antimicrobial Resistance (AMR).

Supporting AMR innovations. Investment, national capability, AMR prevention. Funded by CSIRO, Australia’s National Science Agency, this program supports early-stage biomedical technologies focused on addressing antimicrobial resistance through innovative approaches.

The Minimising Antimicrobial Resistance Stream provides non-dilutive grant funding of up to $500,000 per project for technologies that improve the prevention, detection, diagnosis, or response to emerging and existing antimicrobial resistance challenges. Awardees of the Minimising Antimicrobial Resistance Stream can be found here .

Awardees who met key milestones were eligible to apply for additional ‘top-up’ funding, which further supported their journey towards successful commercialisation. Brandon Biocatalyst is managed by Brandon Capital Email: info@brandonbiocatalyst. com Suite 2.

05, 1 York Street Email: info@brandonbiocatalyst. com